Milestone Scientific Receives CE Mark Approval of Pain-Free Single Tooth Anesthesia (STA(TM)) System
LIVINGSTON, N.J., June 20 /PRNewswire-FirstCall/ -- Milestone Scientific, Inc. (OTC Bulletin Board: MLSS), the recognized leader in advanced injection technologies, today announced that it has been granted CE Mark approval for its award winning Single Tooth Anesthesia (STA(TM)) System. This approval permits the Company to begin marketing the STA System to dental professionals in European Union countries and other countries around the world that recognize the CE Mark approval process.
"We are very pleased to receive CE Mark approval for the STA System, which represents yet another key step forward in the execution of our global marketing and commercialization strategy for this novel product," stated Leonard Osser, Chairman and CEO of Milestone Scientific. "Considering key countries within the European Union will boast a near $33 billion collective market for professional dentistry services in 2008, according to the recent Barnes Report, this presents a compelling growth opportunity for Milestone and gives us more than ample customer targets to pursue as we advance STA's worldwide market penetration initiatives."
The FDA-cleared STA System, recently distinguished as a "2007 Top 100 Product" by leading industry publication Dentistry Today, is comprised of a computer-controlled drive unit and a single-use disposable handpiece/needle assembly. It provides newly-patented, real-time visual and audible feedback and verbal announcements via Milestone's patented CompuFlo(TM) with Dynamic Pressure Sensing (DPS(TM)) technology, thus taking the guesswork out of the administration of anesthetic. Specifically, the STA System enables the dental professional to precisely administer an intraligamentary injection to anesthetize a single tooth in only one or two minutes, rather than administering a mandibular block that anesthetizes an entire quadrant. The STA intraligamentary injection has an immediate onset, whereas the typical block injection can take eight to 12 minutes before a dentist can start treatment. The dental literature shows that approximately 30 percent of mandibular block injections are missed due to limitations of technique and delivery. This can add another five to ten minutes to the time a patient has to wait to be reinjected by the dentist. In addition, the STA intraligementary injection lasts as long as a traditional infiltration or mandibular block. All of this is accomplished with a technology that has been clinically proven to provide a pain-free injection. For more information, contact Milestone Scientific at (877) STA-IS4U or visit http://www.STAIS4U.com.
About Milestone Scientific, Inc.
Headquartered in Livingston, New Jersey, Milestone Scientific is engaged in pioneering proprietary, highly innovative technological solutions for the medical and dental markets. Central to the Company's IP platform and product development strategy is its patented CompuFlo(TM) technology for the improved and painless delivery of local anesthetic. Specifically, CompuFlo is a computer-controlled, pressure sensitive infusion, perfusion, suffusion and aspiration technology, which provides real-time readouts of pressures, fluid densities and flow rates, enabling the advanced delivery and removal of a wide array of fluids. The Single Tooth Anesthesia (STA(TM)) computer-controlled local anesthesia delivery system which uses this technology provides dentists with audible and visual signals as to in-tissue pressure. Milestone's existing painless injection systems are currently sold in 25 countries. For more information on these and other innovative Milestone products, please visit the Company's web site found at http://www.milesci.com.
Safe Harbor Statement
This press release contains forward-looking statements regarding the timing and financial impact of the Milestone's ability to implement its business plan, expected revenues and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report on Form 10-KSB for the year ended December 31, 2006. The forward looking-statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.
FOR MORE INFORMATION, PLEASE CONTACT: Elite Financial Communications Group, LLC Dodi Handy, President and CEO, or Daniel Conway, Chief Strategist 407-585-1080 or via email at email@example.com
SOURCE Milestone Scientific, Inc.
Released June 20, 2007